Some teams have said that they would like to continue their projects. Below is the list I have heard about plus team leads.
Kidney Cancer Biology
Dr. Gabriel G. Malouf MD, PhD provides a good overview of rare kidney cancers at the molecular level for patients and physicians.
Presented at the 2016 GUASCO conference in San Francisco
Elizabeth Y. Wei and James J. Hsieh
Elizabeth Y Wei, Ying-Bei Chen, James J Hsieh
Metastatic non-clear cell renal cell carcinoma: an evidence based review of current treatment strategies
Alexander Sankin, A. Ari Hakimi, James J. Hsieh and Ana M. Molina
Emerging Reclassification Schemes of RCC: How Identifying New Molecular Entities Among Non-Clear Cell RCC Signifies an Evolution in Managing the Disease
James Hsieh, MD, PhD
This is the first of a two-part series on reclassification of renal cell carcinomas (RCCs), many of which are con- sidered non-clear cell RCC (nccRCC). The first part will
The International Society of Urological Pathology (ISUP) Vancouver Classification of Renal Neoplasia
John R. Srigley, MD, Brett Delahunt, MD, John N. Eble, MD, Lars Egevad, MD, PhD,
Jonathan I. Epstein, MD, David Grignon, MD, Ondrej Hes, MD, PhD, Holger Moch, MD,
Rodolfo Montironi, MD, Satish K. Tickoo, MD, Ming Zhou, MD, PhD,
Pedram Argani, MD, and The ISUP Renal Tumor Panel